Testing effectiveness (Phase 2)Ended earlyNCT00493454
What this trial is testing
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 6
Showing 20 of 0 results